ABL1 S417Y

CI-VAR-00004059Explore in graph →NP_005148.2:p.Ser417TyrNM_005157.5:c.1250C>ACIViC 1613

Curated evidence

Evidence by cancer (4 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–4 of 4 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Chronic Myeloid Leukemia, BCR-ABL1 Positive4
ABL1 S417Y	Imatinib	Predictive	C	Supports Resistance	2	rejected	EID8089 In this study, patients on imatinib monotherapy were monitored for ABL1 kinase domain variants in BCR-ABL1 fusions amplified from peripheral blood RNA. Among 64 patients initially in late-chronic phas… (full text at CIViC) PMID 12623848 · Branford et al., 2003 · Open in CIViC	civic
BCR::ABL1 Fusion AND ABL1 S417Y	Dasatinib	Predictive	C	Supports Sensitivity Response	2	submitted	EID4712 In a retrospective study of 174 imatinib-resistant or -intolerant Philadelphia chromosome BCR-ABL1fusion positive accelerated phase chronic myeloid leukemia patients, patients with mutations in the AB… (full text at CIViC) PMID 19487385 · Apperley et al., 2009 · Open in CIViC

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.